Literature DB >> 22922139

Identification of the genes expression profile associated with the ex vivo resistance to etoposide in childhood acute leukemias.

Joanna Szczepanek1, Jan Styczyński, Andrzej Tretyn, Monika Pogorzała, Mariusz Wysocki.   

Abstract

INTRODUCTION: Drug resistance and the gene expression profiles might discriminate the therapy outcome, and indicate the subgroup of patients with poor prognosis. In this study we analyzed the gene expression profile in correlation with the profile of ex vivo resistance to etoposide in children with acute leukemias.
METHODS: The ex vivo drug resistance profile was determined by the MTT cytotoxicity assay performed on leukemic blasts of 56 patients. Gene expression profiles were obtained from the results of hybridization of cRNA to Human Genome U133A 2.0 ologonucleotide arrays. The following analyses were performed: correlation analysis, hierarchical clustering, the assignment of location and function. Verification of data for four selected genes (MNDA, GH1, NUDT21, RHOG) was performed by quantitative real time polymerase chain reaction in the studied population and in an independent group of 54 leukemic patients.
RESULTS: Using the permutation Spearman correlation test, a set of 233 probes/209 genes was selected. The global test confirmed the significance of the correlation of gene expression profile and resistance to etoposide (p<0.001). The NUDT21 (nudix, nucleoside diphosphate linked moiety X-type, motif 21) gene showed the strongest correlation with resistance to etoposide (FDR<0.0001%).
CONCLUSIONS: Profiling of transcriptome may help in assessing the sensitivity to drugs used in chemotherapy. Resistance to etoposide is possibly associated with a change of expression of a large number of biologically important genes that influence several cellular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922139     DOI: 10.5604/17322693.1000903

Source DB:  PubMed          Journal:  Postepy Hig Med Dosw (Online)        ISSN: 0032-5449            Impact factor:   0.270


  2 in total

Review 1.  CFIm25 and alternative polyadenylation: Conflicting roles in cancer.

Authors:  Mohammad Hassan Jafari Najaf Abadi; Rana Shafabakhsh; Zatollah Asemi; Hamid Reza Mirzaei; Roxana Sahebnasagh; Hamed Mirzaei; Michael R Hamblin
Journal:  Cancer Lett       Date:  2019-06-07       Impact factor: 8.679

2.  Knockdown of NUDT21 inhibits proliferation and promotes apoptosis of human K562 leukemia cells through ERK pathway.

Authors:  Lan Zhang; Weihua Zhang
Journal:  Cancer Manag Res       Date:  2018-10-08       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.